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Abstract
5HTTLPR polymorphism of serotonin transporter yields short (S) and long (L) alleles. SS and LS genotypes are associated
with reduced expression of serotonin transporter. This cross-sectional study investigated the association of 5HTTLPR with
symptom severity of irritable bowel syndrome (IBS). Patients with IBS (Rome III) and healthy controls were included.
Genomic DNA was extracted from saliva, and 5HTTLPR alleles were assessed by polymerase chain reaction. IBS symptom
severity was evaluated by means of IBS-SSS questionnaire. Two hundreds and four IBS patients (159 females; mean age:
39.6612.3 years; 106 with constipation: C-IBS; 98 with diarrhea: D-IBS) and 200 healthy controls (154 females; mean age:
40.4615.8 years) were enrolled. The overall IBS-SSS value was higher in LS/SS than LL patients (319.0671.5 versus
283.8662.3; P = 0.0006). LS/SS patients had also higher values of abdominal pain (59.7621.0 versus 51.0618.8; P = 0.020)
and bowel dissatisfaction (80.1623.9 versus 70.5622.8; P = 0.035). The overall IBS-SSS values in C-IBS and D-IBS patients
were 317.2668.3 and 296.1671.4, respectively (P = 0.192), with significantly higher values for abdominal distension
(65.0624.4 versus 51.4624.8; P = 0.0006), but not for bowel dissatisfaction (80.5621.7 versus 72.9625.7; P = 0.138).
Frequencies of 5HTTLPR genotypes did not differ significantly when comparing IBS patients (overall or upon stratification in
C-IBS and D-IBS) with healthy controls. In conclusion, the LS and SS genotypes are significantly correlated with IBS symptom
severity, although their possible direct causal role remains to be proven. In addition, the present findings do not support an
association of 5HTTLPR with IBS or its clinical presentation in terms of bowel habit predominance.
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Introduction
Irritable bowel syndrome (IBS) is a functional digestive disorder
characterized by abdominal pain/discomfort and changes in
bowel habit (constipation and/or diarrhoea), which can be
associated with alterations of gastrointestinal (GI) transit, visceral
hypersensitivity and psychopathological comorbidities. [1,2] Ow-
ing to its chronicity and substantial lack of effective cures, IBS
results in a significant social burden, with a loss of work
productivity, impaired quality of life, and a remarkable use of
health care resources. [3].
From a pathogenic standpoint, IBS is a complex, heterogeneous
disorder, whose development is widely considered as multifactorial
in nature. [4,5] Based on current evidence, a gene-environment
paradigm has been proposed for IBS, whereby a combination of
genetic determinants and environmental factors gives rise to
alterations in GI sensation and motor functions, that ultimately
account for the occurrence of symptoms. [6,7] In this context,
studies on families or twins have given support to the hypothesis of
a genetic background in IBS and, consequently, intensive efforts
are being made to evaluate whether specific polymorphisms of a
number of candidate genes are pathogenically associated with IBS.
[6,8] Furthermore, since genetic factors do not act necessarily as
risk factors, but they can also impact on clinical phenotypes, great
attention is being paid also to possible relationships linking genetic
polymorphisms to intermediate phenotypes (e.g., GI transit and
pain threshold to rectal distension) or clinical presentation/
severity. [9,10,11].
The involvement of serotonin (5-HT) in the pathophysiology of
IBS is also an area of active investigation, owing to its presence in
both GI tract and brain. Indeed, 5-HT acts as a main regulator of
GI motility, secretion and sensory signalling, and plays also a
pivotal role in the control of mood at level of the central nervous
system (CNS). [12,13] The magnitude and duration of 5-HT
actions depend mostly on 5-HT transporter (SERT), which
mediates the extracellular reuptake of 5-HT, thus ensuring its
recycling and catabolic breakdown. [14,15] Since abnormalities in
5-HT reuptake have the potential of altering the enteric
serotonergic signalling, leading to motor, secretory and sensory
gut dysfunctions, it has been suggested that genetic or epigenetic
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SERT variations might contribute to the pathogenesis or clinical
presentation of IBS. [7,16].
The promoter region of human SERT gene contains a
polymorphism, designated as ‘5-HT transporter length polymor-
phic region’ (5HTTLPR), which consists of a 44-base pair
deletion/insertion, resulting in a short (S) and long (L) allele.
[17,18] The implications of this polymorphism in IBS are
currently under evaluation since, as compared with LL genotype,
SS or SL genotypes are associated with lower levels of SERT
mRNA transcripts, and thereby lower levels of SERT expression
and lower efficiency of 5-HT reuptake. [19,20,21] A meta-analysis
of association studies has not supported a pathogenic link of
5HTTLPR with IBS. [22] By contrast, some studies have found a
significant association when IBS patients were stratified by their
predominant bowel habit, [23] or were investigated for pain
sensation at rectal distension or somatic symptom scores. [10,24]
However, whether 5HTTLPR exerts any influence on symptom
severity in IBS remains undetermined. Accordingly, the present
study was carried out with the primary purpose of investigating a
possible association of 5HTTLPR polymorphism with overall
symptom severity in IBS patients.
Methods
Study Aims
The primary objective was to examine the association of
5HTTLPR with the overall symptom severity in IBS patients. The
secondary objectives were: 1) to evaluate the association of
5HTTLPR with the severity of different symptoms; 2) to evaluate
the overall symptom severity and the severity of different IBS
symptoms in patients with predominance of constipation (C-IBS)
or diarrhoea (D-IBS); 3) to evaluate the association of 5HTTLPR
with IBS in all IBS patients, as well as in the subgroups of C-IBS or
D-IBS, by comparisons with healthy controls.
Study Design and Population
This study was conducted on native Italians of Caucasian
origin, gender of either sex, age equal or higher than 18 years, and
diagnosis of IBS according to Rome III criteria, [1] referred
consecutively to the Unit of Gastroenterology from June 2009 to
December 2011. Exclusion criteria included: severe organic
diseases; history of major abdominal surgery; severe psychiatric
disorders; significant alterations of blood chemistry, haematology,
and urine analysis; organic lesions at colonoscopy, barium enema,
or abdominal ultrasonography; lactose intolerance; treatment with
any drug, employed for IBS or affecting the digestive system or
CNS, within the previous month. IBS patients with alternation of
diarrhea and constipation were also excluded, since changes in the
clinical phenotype are common in this subpopulation. [25] To
evaluate the association of 5HTTLPR with IBS, healthy
volunteers, consisting of native Italians of Caucasian origin,
gender of either sex, and age equal or higher than 18 years, were
also enrolled. The exclusion criteria included: body mass index
lower than 19 or higher than 25 kg/m2; unremarkable medical
history; any functional or organic disease; history of major
abdominal surgery; severe psychiatric disorders; food intolerance;
any hematologic abnormality.
Experimental Design
At least two samples of saliva were collected from each IBS
patient and healthy volunteer in different days and stored at
220uC. All subsequent analytical procedures were performed at
the Division of Pharmacology and Chemotherapy. The severity of
IBS symptoms was evaluated by the questionnaire IBS-Symptom
Severity Score (IBS-SSS). [26] Then all patients received the
standard of care. The study protocol was approved by the Ethical
Committee of Pisa and was carried out in accordance with the
Helsinki Declaration (Edinburgh revision, 2000). A signed
informed consent was obtained from each participant.
5HTTLPR Polymorphism Assay
Genomic DNA was isolated from saliva by the alkaline method
using QIAamp DNA blood MINI kit (Qiagen, Milano, Italy),
quantified by spectrophotometry, and visualized by agarose gel
electrophoresis. At the first run, success rates of 97.5% and 95.5%
were obtained for DNA extraction in IBS patients and healthy
controls, respectively. Additional samples of saliva were then
employed or collected again from subjects with extraction failure,
and success rates of 100% were achieved at the second run of
genomic DNA extraction. In order to avoid and properly manage
genotyping errors, for each batch the following cautions were
taken as suggested by Pompanon et al. [27]: 1) the laboratory staff
was blinded to sample allocation; 2) blanks and duplicate samples
of control DNA were included; 3) each sample was assayed in
duplicate; 4) cases of genotyping failure in at least one duplicate
were resolved by assaying DNA extracted from additional samples
of saliva; 5) care was taken to verify whether the genotype
distribution was in Hardy-Weinberg equilibrium. The 5HTTLPR
polymorphism was typed by polymerase chain reaction (PCR)
using the following oligonucleotide primers: forward (LPR-F), 59-
GGCGTTGCCGCTCTGAATGC-39, spanning from nucleotide
–1416 to –1397; reverse (LPR-R), 59-GAGGGACTGAGCTG-
GACAACCAC-39, spanning from –910 to –888. PCR was
performed with the GC-Rich PCR system (Roche Molecular
Biochemicals), in a 50-ml reaction containing 1 ml of genomic
DNA (20–50 ng), 25 ml of DNAase free H2O, 1 ml of 10 mM
dNTP, 1 ml of 10 mM LPR-F primer, 1 ml of 10 mM LPR-R
primer, 10 ml of BUFFER GC resolution, 10 ml of BUFFER 56
DMSO and 1 ml of AmpliTaq polymerase enzyme (ROCHE
Diagnostics, Milano, Italy). DNA was denatured at 94uC for 3 min
and subjected to 35 cycles of 1 min of denaturation at 94uC, 1 min
of annealing at 55uC, 1 min of extension at 72uC, and 7 min of
final extension at 72uC. Amplification products were resolved by
electrophoresis on 2% agarose gel, and visualized with ethidium
bromide staining. The image was acquired by means of a Kodak
Image Station 440. The alleles containing the S or L variant of
5HTTLPR yielded PCR products of 528 and 572 base pairs,
respectively. Based on PCR results, the enrolled subjects were
classified as having the LL, LS or SS genotype.
Evaluation of Symptom Severity
The IBS-SSS questionnaire takes into account the following
items: a) presence and severity of abdominal pain or discomfort; b)
frequency of abdominal pain or discomfort; c) presence and
severity of abdominal distension; d) degree of satisfaction of
defecatory behaviour; e) degree of interference of IBS symptoms
with daily lifestyle. Each of the above items generates a maximum
score of 100, leading to an overall score of 500. [26].
Endpoints
Primary endpoint: overall IBS-SSS value, to compare LL versus
LS/SS genotypes in patients. Secondary endpoints: 1) value of
each IBS-SSS item, to compare LL versus LS/SS genotypes in
patients; 2) overall IBS-SSS value, to compare C-IBS versus D-IBS
patients; 3) value of each IBS-SSS item, to compare C-IBS versus
D-IBS patients; 4) frequencies of LL and LS/SS genotypes, to
compare IBS patients with healthy volunteers; 5) frequencies of LL
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and LS/SS genotypes, to compare C-IBS patients, D-IBS patients
and healthy volunteers.
Statistical Analysis
Data were expressed as mean 6 standard deviation (SD) for
continuous variables, and as percentage for qualitative variables.
Comparisons between groups were performed by analysis of
variance (ANOVA) and the non-parametric Wilcoxon unpaired
test for continuous variables, and by the Pearson’s chi-square or
the Fisher’s exact test for categorical variables. Adjustments for
multiple comparisons were carried out by the Bonferroni
correction. Comparisons between groups for IBS-SSS values were
also performed by a two-factor (genotype and IBS subgroups)
ANOVA, and the two-factor interaction was evaluated. The
patients sample size was determined to evaluate a between-groups
(LL versus LS/SS genotype) difference of 30 in the mean overall
IBS-SSS value, with a standard deviation of 65, a first type error of
0.05 and a power of 0.80. A 2-sided P value ,0.05 was considered
to be statistically significant. Statistical analysis was performed by
JMP 4.0 (SAS Institute Inc., Cary, NC, U.S.A.) and StatXact-4
(Cytel Software Corporation, Cambridge, MA, U.S.A.).
Results
Influence of 5HTTLPR Genotypes on IBS Symptom
Severity
Two hundreds and four consecutive patients (45 males, 159
females; mean age: 39.6612.3 years), with a diagnosis of C-IBS (6
males, 100 females; mean age: 41.2612.9 years) or D-IBS (39
males, 59 females; mean age: 38.0611.5 years), were enrolled to
assess the relationship between 5HTTLPR genotypes and IBS
symptom severity. The C-IBS and D-IBS subgroups differed
significantly for male/female proportion (P,0.0001), but not for
age. For the purpose of analyzing the primary and secondary
endpoints, the subjects with SS and LS genotypes were pooled
(LS/SS), since the S allele has been reported to be dominant and
both SS and LS genotypes have been associated with a lower
SERT expression and reduced efficiency of 5-HT uptake, as
compared with the LL genotype. [17,18] However, in order to
perform additional exploratory evaluations, subjects with geno-
types LS and SS were also analysed as separate groups.
The overall mean symptom severity, as assessed by IBS-SSS,
was significantly higher in patients with LS/SS than LL genotype
(Table 1). When comparing the mean values obtained for each
IBS-SSS item, ‘abdominal pain severity’ and ‘bowel dissatisfaction’
were significantly higher in patients with LS/SS than LL
genotype, while no significant differences were found with regard
for the ‘occurrence of pain over the preceding 10 days’,
‘abdominal distension severity’, and ‘interference with quality of
life’ (Table 1). These findings were confirmed also when the P
values were adjusted for multiple comparisons by the Bonferroni
correction. Of note, an exploratory analysis showed that, when
comparing patients with LS and SS genotypes as separate groups,
there were no significant differences with regard for the overall
symptom severity (P = 0.496) and single-item IBS-SSS values
(abdominal pain severity, P= 0.935; occurrence of pain over the
preceding ten days, P= 0.348; abdominal distension severity,
P = 0.968; bowel dissatisfaction, P= 0.309; interference with
quality of life, P = 0.851).
Symptom severity was assessed also in C-IBS and D-IBS
patients. The overall mean IBS-SSS values were found to be
significantly higher in the C-IBS than D-IBS subgroup, irrespec-
tively of their 5HTTLPR genotype (Table 2). Likewise, when
evaluating symptom severity by single items, the score values for
‘abdominal distension severity’ and ‘bowel dissatisfaction’ were
significantly higher in C-IBS than D-IBS patients (Table 2).
However, upon application of Bonferroni correction, the signifi-
cance of differences in terms of overall symptom severity and
bowel dissatisfaction were lost (P = 0.192 and 0.138, respectively),
while the significance of differences concerning abdominal
distension severity was confirmed (P = 0.0006).
There was a lack of significant interaction between bowel habits
(i.e., C-IBS and D-IBS) and 5HTTLPR genotypes, indicating no
effect modification and independent effects of bowel habits and
genotypes on symptom severity (interaction P values: 0.297 for
overall IBS-SSS value; 0.078 for abdominal pain severity; 0.481
for occurrence of pain over the preceding 10 days; 0.811 for
abdominal distension severity; 0.379 for bowel dissatisfaction;
0.406 for interference with quality of life).
Association of 5HTTLPR Polymorphism with IBS
In order to evaluate whether 5HTTLPR polymorphism is
associated with IBS in the present group of patients, a comparison
was made with a group of healthy controls. For this purpose, 200
healthy volunteers (46 males, 154 females; mean age: 40.4615.8
years) were enrolled in the study. They did not differ significantly
in terms of male/female proportion and mean age from the group
of IBS patients.
The frequencies of 5HTTLPR genotypes in IBS patients and
healthy volunteers are displayed in Table 3. Care was taken to
verify that the genotype distribution in healthy volunteers was in
Hardy-Weinberg equilibrium (chi-square = 0.21, P= 0.646). In
order to allow comparisons with previous observations, the LS and
SS genotypes were analyzed either separately or as a pooled group
(LS/SS). In both cases, the frequencies of LL, LS, SS or LS/SS
genotypes in IBS patients did not differ significantly from those
estimated in healthy volunteers (Table 3). Likewise, genotypes
frequencies did not differ significantly when the comparisons were
conducted on IBS patients after their stratification into two
subgroups, according to the predominance of constipation or
diarrhea (Table 4).
Discussion
Great attention is currently revolving around the pathogenic
bases and pathophysiological mechanisms accounting for the
clinical manifestations of IBS, [4,5] and there is consistent
evidence suggesting an influence of genetic factors on this disorder.
[6,8] In this context, our study provides the first evidence that
5HTTLPR impacts on the severity of IBS symptoms. In
particular, our findings point out a higher degree of symptom
severity in patients with at least one S allele, and suggest that the S
variant affects mainly the severity of abdominal pain and bowel
dissatisfaction. Of note, our exploratory analysis showed that IBS-
SSS values did not differ significantly when comparing subgroups
with LS and SS genotypes, thus suggesting that the group of
patients with pooled LS/SS genotypes was a homogeneous
population.
The contention that the LS/SS genotypes can increase the
severity of IBS symptoms, with particular regard for abdominal
pain, is supported by previous investigations. In particular our
findings are in line with data from Camilleri et al. [10] who found
that the LS/SS genotypes are associated with increased pain
sensation at rectal distension. Taken together, these observations
[10] and our results are consistent with the notion that the S allele
is expected to impair the efficiency of 5-HT reuptake with a
consequent prolonged and enhanced activation of serotonergic
pathways mediating abdominal pain sensation. Therefore, it can
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be argued that the reduced 5-HT re-uptake could induce an
overstimulation of extrinsic nerve afferents resulting in neuronal
sensory sensitisation, which might occur at peripheral, spinal, or
even higher CNS levels. [23,28] In this regard, an interesting study
by Fukudo et al. [29], aimed at evaluating the link between
5HTTLPR and differential activation of brain regions by
colorectal distention in humans, displayed that individuals with a
weak function of serotonin transporter (i.e. S/S genotype)
responded to signals from gut with higher intensity in emotion-
regulating brain regions, thus suggesting that this functional gene
polymorphism may partly predict the individual effects of selective
serotonin reuptake inhibitors on visceral pain. [29].
Whether the influence of 5HTTLPR on abdominal pain results
mainly from peripheral or central mechanisms, or both, is
presently unknown and remains open to future investigations.
However, some evidence suggests that central mechanisms may
contribute to the enhanced pain perception in IBS patients with
LS/SS genotypes: 1) specific brain regions of IBS patients and
healthy controls are subjected to differential activation upon
application of rectal stimuli; [30] 2) brain regions highly related to
pain recognition and emotion (e.g. anterior cingulated cortex)
were found to be more activated by distension of descending colon
in IBS patients, [9] and altered interactions between anterior
cingulated cortex and amygdala have been reported in subjects
with LS/SS genotypes; [31] 3) individuals with the SS genotype
were more likely to activate these CNS regions, thus suggesting
that the S variant can be relevant in brain activation after
colorectal distension in IBS patients. [11] Further support to the
contribution of central nervous mechanisms on the association of
5HTTLPR with symptom severity in IBS comes from the
observations that: 1) in IBS patients, the LS/SS genotypes were
associated with high values of somatic symptom scores, suggesting
that 5-HTTLPR is implicated in the responses of IBS patients to
stress; [24] 2) individuals with the S allele display higher
vulnerability to stressful life events and are more prone to develop
depressive symptoms. [32]. In this respect, to assess whether the
influence of S allele on abdominal pain severity, could be related
to differences in patients’ psychopathological traits would be of
high interest, and this issue deserves future investigations.
In the present study, when the P values were adjusted for
multiple comparisons, the analysis for secondary endpoints
revealed that the overall symptom severity did not differ in C-
and D-IBS patients, while the analysis of single severity items
displayed significant differences only for the severity of abdominal
distension. Moreover, our analysis showed a lack of significant
interaction between bowel habits and 5HTTLPR genotypes.
These findings were not completely unexpected, since C-IBS
patients are known to complain of abdominal distension more
than D-IBS patients. [33] In addition, and most importantly, these
data argue against the possibility that the differential influences of
5HTTLPR genotypes on abdominal pain severity might result
from differences in bowel habit.
The influence of 5HTTLPR on IBS symptom severity and,
particularly, on abdominal pain severity, might have interesting
implications for the effectiveness and/or safety of drugs proposed
for the therapeutic management of this syndrome. SERT is a
specific target of ‘selective serotonin reuptake inhibitors’ (SSRIs)
and there is evidence linking 5HTTLPR to the efficacy and safety
of these drugs in patients with depression. [34,35] It is being also
appreciated that SSRIs can exert beneficial effects on IBS, with
particular regard for the control of abdominal discomfort or pain,
[16,36] but whether SERT polymorphisms may influence such
therapeutic responses remains unknown.
Table 1. Mean values (6 standard deviation) of overall and single-item IBS-SSS in patients with LL versus LS/SS genotype.
LL (n=69) LS/SS (n=135) P P (*)
Abdominal pain severity 51.0618.8 59.7621.0 0.004 0.020
Occurrence of pain over the preceding 10 days 50.4626.4 55.4629.8 0.089 0.445
Abdominal distension severity 56.4624.7 59.5625.9 0.401 1,000
Bowel dissatisfaction 70.5622.8 80.1623.9 0.007 0.035
Interference with quality of life 55.7625.9 62.1628.3 0.116 0.580
Overall score 283.8662.3 319.0671.5 0.0006
(*) P values after Bonferroni correction.
doi:10.1371/journal.pone.0054831.t001
Table 2. Mean values (6 standard deviation) of overall and single-item IBS-SSS in IBS patients with predominance of constipation
(C-IBS) or diarrhea (D-IBS).
C-IBS (n=106) D-IBS (n=98) P P (*)
Abdominal pain severity 57.5620.8 55.9620.6 0.563 1,000
Occurrence of pain over the preceding 10 days 56.6630.5 53.3627.9 0.424 1,000
Abdominal distension severity 65.0624.4 51.4624.8 0.0001 0.0006
Bowel dissatisfaction 80.5621.7 72.9625.7 0.023 0.138
Interference with quality of life 57.6627.6 62.5627.5 0.210 1.000
Overall score 317.2668.3 296.1671.4 0.032 0.192
(*) P values after Bonferroni correction.
doi:10.1371/journal.pone.0054831.t002
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To date, most of the studies on the impact of 5-HT genetics on
IBS have investigated the associations of 5HTTLPR with its
pathogenesis or clinical presentation. In this regard, the present
study was conducted also with the secondary objective of
evaluating whether any of such associations could be highlighted
in our IBS patients. For this purpose, the frequencies of their
5HTTLPR genotypes were compared with those of healthy
controls, selected with similar demographic characteristics, and no
significant association was found either for the overall IBS group
or for the subgroups of C-IBS and D-IBS patients. Our results are
consistent with the majority of previous studies [6,22] which failed
in finding a link between 5HTTLPR and IBS. Moreover, while
most authors did not find specific links of 5HTTLPR with C-IBS
or D-IBS, [24,37,38,39,40] others have reported significant
associations of SS with D-IBS, [23,41] SS with C-IBS, [42] or
LL with C-IBS. [10,21,43] Among the variety of factors which
might account for the heterogeneity of these observations, the
most relevant relies perhaps in the different distribution of
5HTTLPR genotypes among different populations. In particular,
the allele frequencies between Caucasian and Asian populations
are different, since S allele is found in 42% of Caucasians and in
79% of Asians. [44] Furthermore, significant variations in the
frequency of 5HTTLPR genotypes can be found even in
populations sharing the same Caucasian origin, but belonging to
distinct ethnicities. [44] In this respect, both the IBS patients and
healthy volunteers evaluated in our study were highly homoge-
neous, as we enrolled only white Caucasian subjects of Italian
origin.
In conclusion, the present study suggests that the LS and SS
genotypes are significantly correlated with IBS symptom severity,
although their possible direct causal role remains to be proven. In
addition, the present findings do not support an association of
5HTTLPR with IBS or its clinical presentation in terms of bowel
habit predominance.
Author Contributions
Conceived and designed the experiments: CB MB RC SM NDB.
Performed the experiments: RC NG GR. Analyzed the data: RC DG
AR MGM NG MF LA MT. Contributed reagents/materials/analysis
tools: NG MGM DG. Wrote the paper: MB CB SM FC GR.
References
1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, et al.
(2006) Functional bowel disorders. Gastroenterology 130: 1480–1491.
2. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, et al.
(2009) An evidence-based position statement on the management of irritable
bowel syndrome. Am J Gastroenterol 104 Suppl 1: S1–35.
3. Spiller R (2007) Clinical update: irritable bowel syndrome. Lancet 369: 1586–
1588.
4. Ohman L, Simren M (2007) New insights into the pathogenesis and
pathophysiology of irritable bowel syndrome. Dig Liver Dis 39: 201–215.
5. Hasler WL (2011) Traditional thoughts on the pathophysiology of irritable bowel
syndrome. Gastroenterol Clin North Am 40: 21–43.
6. Saito YA (2011) The role of genetics in IBS. Gastroenterol Clin North Am 40:
45–67.
7. Camilleri M, Katzka DA (2012) Genetic epidemiology and pharmacogenetics in
irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 302: G1075–
1084.
8. Adam B, Liebregts T, Holtmann G (2007) Mechanisms of disease: genetics of
functional gastrointestinal disorders–searching the genes that matter. Nat Clin
Pract Gastroenterol Hepatol 4: 102–110.
9. Hamaguchi T, Kano M, Rikimaru H, Kanazawa M, Itoh M, et al. (2004) Brain
activity during distention of the descending colon in humans. Neurogastroen-
terol Motil 16: 299–309.
10. Camilleri M, Busciglio I, Carlson P, McKinzie S, Burton D, et al. (2008)
Candidate genes and sensory functions in health and irritable bowel syndrome.
Am J Physiol Gastrointest Liver Physiol 295: G219–225.
11. Fukudo S, Kanazawa M, Mizuno T, Hamaguchi T, Kano M, et al. (2009)
Impact of serotonin transporter gene polymorphism on brain activation by
colorectal distention. Neuroimage 47: 946–951.
12. Kim DY, Camilleri M (2000) Serotonin: a mediator of the brain-gut connection.
Am J Gastroenterol 95: 2698–2709.
13. Gershon MD (2005) Nerves, reflexes, and the enteric nervous system:
pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol 39: S184–
193.
14. Chen JX, Pan H, Rothman TP, Wade PR, Gershon MD (1998) Guinea pig 5-
HT transporter: cloning, expression, distribution, and function in intestinal
sensory reception. Am J Physiol 275: G433–448.
15. Mawe GM, Coates MD, Moses PL (2006) Review article: intestinal serotonin
signalling in irritable bowel syndrome. Aliment Pharmacol Ther 23: 1067–1076.
16. Colucci R, Blandizzi C, Bellini M, Ghisu N, Tonini M, et al. (2008) The genetics
of the serotonin transporter and irritable bowel syndrome. Trends Mol Med 14:
295–304.
17. Heils A, Teufel A, Petri S, Stober G, Riederer P, et al. (1996) Allelic variation of
human serotonin transporter gene expression. J Neurochem 66: 2621–2624.
18. Lesch KP (2001) Variation of serotonergic gene expression: neurodevelopment
and the complexity of response to psychopharmacologic drugs. Eur Neuropsy-
chopharmacol 11: 457–474.
19. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, et al. (1996) Association
of anxiety-related traits with a polymorphism in the serotonin transporter gene
regulatory region. Science 274: 1527–1531.
20. Hranilovic D, Stefulj J, Schwab S, Borrmann-Hassenbach M, Albus M, et al.
(2004) Serotonin transporter promoter and intron 2 polymorphisms: relationship
between allelic variants and gene expression. Biol Psychiatry 55: 1090–1094.
21. Wang YM, Chang Y, Chang YY, Cheng J, Li J, et al. (2012) Serotonin
transporter gene promoter region polymorphisms and serotonin transporter
expression in the colonic mucosa of irritable bowel syndrome patients.
Neurogastroenterol Motil 24: 560–e255.
22. Van Kerkhoven LA, Laheij RJ, Jansen JB (2007) Meta-analysis: a functional
polymorphism in the gene encoding for activity of the serotonin transporter
protein is not associated with the irritable bowel syndrome. Aliment Pharmacol
Ther 26: 979–986.
23. Yeo A, Boyd P, Lumsden S, Saunders T, Handley A, et al. (2004) Association
between a functional polymorphism in the serotonin transporter gene and
diarrhoea predominant irritable bowel syndrome in women. Gut 53: 1452–
1458.
24. Kim HJ, Camilleri M, Carlson PJ, Cremonini F, Ferber I, et al. (2004)
Association of distinct alpha(2) adrenoceptor and serotonin transporter
Table 3. Frequencies of 5HTTLPR genotypes in IBS patients
and healthy volunteers (HV).
IBS (n =204) HV (n=200) P
LL 69 (33.8%) 60 (30.0%) 0.657 (a)
LS 101 (49.5%) 102 (51.0%)
SS 34 (16.7%) 38 (19.0%)
LS/SS 135 (66.2%) 140 (70.0%) 0.455 (b)
(a) comparison by LL, LS and SS subgroups.
(b) comparison by LL and LS/SS subgroups.
doi:10.1371/journal.pone.0054831.t003
Table 4. Frequencies of 5HTTLPR genotypes in IBS patients
with predominance of constipation (C-IBS) or diarrhea (D-IBS)
and healthy volunteers (HV).
C-IBS (n =106) D-IBS (n =98) HV (n=200) P
LL 36 (33.9%) 33 (33.7%) 60 (30.0%) 0.594 (a)
LS 56 (52.8%) 45 (45.9%) 102 (51.0%)
SS 14 (13.3%) 20 (20.4%) 38 (19.0%)
LS/SS 70 (66.1%) 65 (66.3%) 140 (70.0%) 0.711 (b)
(a) comparison by LL, LS and SS subgroups.
(a) comparison by LL and LS/SS subgroups.
doi:10.1371/journal.pone.0054831.t004
5HTTLPR Polymorphism and IBS Symptom Severity
PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e54831
polymorphisms with constipation and somatic symptoms in functional
gastrointestinal disorders. Gut 53: 829–837.
25. Garrigues V, Mearin F, Badia X, Balboa A, Benavent J, et al. (2007) Change
over time of bowel habit in irritable bowel syndrome: a prospective,
observational, 1-year follow-up study (RITMO study). Aliment Pharmacol Ther
25: 323–332.
26. Francis CY, Morris J, Whorwell PJ (1997) The irritable bowel severity scoring
system: a simple method of monitoring irritable bowel syndrome and its
progress. Aliment Pharmacol Ther 11: 395–402.
27. Pompanon F, Bonin A, Bellemain E, Taberlet P (2005) Genotyping errors:
causes, consequences and solutions. Nature Rev Genet 6: 847–59.
28. Mayer EA, Gebhart GF (1994) Basic and clinical aspects of visceral hyperalgesia.
Gastroenterology 107: 271–293.
29. Fukudo S, Kanazawa M, Mizuno T, Hamaguchi T, Kano M, et al. (2009)
Impact of serotonin transporter gene polymorphism on brain activation by
colorectal distention. Neuroimage 47: 946–951.
30. Mertz H, Morgan V, Tanner G, Pickens D, Price R, et al. (2000) Regional
cerebral activation in irritable bowel syndrome and control subjects with painful
and nonpainful rectal distention. Gastroenterology 118: 842–848.
31. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, et
al. (2005) 5-HTTLPR polymorphism impacts human cingulate-amygdala
interactions: a genetic susceptibility mechanism for depression. Nat Neurosci
8: 828–834.
32. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, et al. (2003) Influence of
life stress on depression: moderation by a polymorphism in the 5-HTT gene.
Science 301: 386–389.
33. Gerson CD, Gerson MJ, Awad RA, Chowdhury A, Dancey C, et al. (2008)
Irritable bowel syndrome: an international study of symptoms in eight countries.
Eur J Gastroenterol Hepatol 20: 659–667.
34. Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, et al. (2004)
Influence of SERTPR and STin2 in the serotonin transporter gene on the effect
of selective serotonin reuptake inhibitors in depression: a systematic review. Mol
Psychiatry 9: 433–441.
35. Serretti A, Calati R, Mandelli L, De Ronchi D (2006) Serotonin transporter
gene variants and behavior: a comprehensive review. Curr Drug Targets 7:
1659–1669.
36. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P (2009) Efficacy of
antidepressants and psychological therapies in irritable bowel syndrome:
systematic review and meta-analysis. Gut 58: 367–378.
37. Lee DY, Park H, Kim WH, Lee SI, Seo YJ, et al. (2004) [Serotonin transporter
gene polymorphism in healthy adults and patients with irritable bowel
syndrome]. Korean J Gastroenterol 43: 18–22.
38. Saito YA, Locke GR, 3rd, Zimmerman JM, Holtmann G, Slusser JP, et al.
(2007) A genetic association study of 5-HTT LPR and GNbeta3 C825T
polymorphisms with irritable bowel syndrome. Neurogastroenterol Motil 19:
465–470.
39. Kohen R, Jarrett ME, Cain KC, Jun SE, Navaja GP, et al. (2009) The serotonin
transporter polymorphism rs25531 is associated with irritable bowel syndrome.
Dig Dis Sci 54: 2663–2670.
40. Niesler B, Kapeller J, Fell C, Atkinson W, Moller D, et al. (2010) 5-HTTLPR
and STin2 polymorphisms in the serotonin transporter gene and irritable bowel
syndrome: effect of bowel habit and sex. Eur J Gastroenterol Hepatol 22: 856–
861.
41. Park JM, Choi MG, Park JA, Oh JH, Cho YK, et al. (2006) Serotonin
transporter gene polymorphism and irritable bowel syndrome. Neurogastroen-
terol Motil 18: 995–1000.
42. Sikander A, Rana SV, Sinha SK, Prasad KK, Arora SK, et al. (2009) Serotonin
transporter promoter variant: Analysis in Indian IBS patients and control
population. J Clin Gastroenterol 43: 957–961.
43. Li Y, Nie Y, Xie J, Tang W, Liang P, et al. (2007) The association of serotonin
transporter genetic polymorphisms and irritable bowel syndrome and its
influence on tegaserod treatment in Chinese patients. Dig Dis Sci 52: 2942–
2949.
44. Noskova T, Pivac N, Nedic G, Kazantseva A, Gaysina D, et al. (2008) Ethnic
differences in the serotonin transporter polymorphism (5-HTTLPR) in several
European populations. Prog Neuropsychopharmacol Biol Psychiatry 32: 1735–
1739.
5HTTLPR Polymorphism and IBS Symptom Severity
PLOS ONE | www.plosone.org 6 February 2013 | Volume 8 | Issue 2 | e54831
